Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.76 |
| ▸ | DRD3 | P35462 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603367 | 0.92 | HRH4 (0.71) | HRH4DRD3DRD2HRH3FGFR1 | |
| SCHEMBL13893625 | 0.91 | HRH4 (0.73) | HRH4DRD3DRD2HRH3PRKAB2 | |
| SCHEMBL602147 | 0.90 | HRH4 (0.71) | HRH4DRD3DRD2HRH3ACHE | |
| SCHEMBL603835 | 0.89 | HRH4 (0.72) | HRH4DRD3DRD2HRH3ACHE | |
| SCHEMBL602191 | 0.89 | HRH4 (0.75) | HRH4DRD3DRD2HRH3ACHE | |
| SCHEMBL2167181 | 0.89 | HRH4 (0.69) | HRH4DRD3DRD2HRH3FGFR1 | |
| SCHEMBL604692 | 0.87 | HRH4 (0.86) | HRH4DRD3DRD2HRH3 | |
| SCHEMBL602145 | 0.86 | HRH4 (0.68) | HRH4DRD3DRD2HRH3 | |
| SCHEMBL605693 | 0.86 | HRH4 (0.73) | HRH4DRD3DRD2HRH3 | |
| SCHEMBL605424 | 0.83 | HRH4 (0.69) | HRH4DRD3DRD2HRH3PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281307-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-12 | — | — | US | claimed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | claimed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2007120690-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885DRD3 1669/4885DRD2 1842/4885 |
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885DRD3 805/4885DRD2 683/4885 |
| US-20090281307-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885DRD3 1669/4885DRD2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.